Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KAT6A | Q92794 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | FABP4 | P15090 | 7/20 | 0.47 |
| ▸ | GPR27 | Q9NS67 | 5/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 6/20 | 0.47 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17331333 | 0.88 | BDKRB1 (0.51) | MAPK1KAT6AKDM4EFFAR4FABP4 | |
| SCHEMBL17347543 | 0.87 | FABP4 (0.49) | LMNAMAPK1KAT6AKDM4EFABP4 | |
| SCHEMBL3717185 | 0.81 | FABP4 (0.63) | LMNAFFAR4FABP4FABP5 | |
| SCHEMBL17331332 | 0.76 | POLB (0.60) | LMNA | |
| SCHEMBL17347430 | 0.76 | FABP4 (0.50) | FABP4FABP5 | |
| SCHEMBL17347421 | 0.75 | ALDH1A1 (0.51) | LMNAMAPK1KAT6AKDM4EFABP4 | |
| SCHEMBL17331321 | 0.74 | ALDH1A1 (0.56) | LMNAMAPK1FFAR4 | |
| SCHEMBL13753137 | 0.73 | L3MBTL1 (0.54) | LMNAMAPK1 | |
| SCHEMBL13753123 | 0.73 | NPC1 (0.66) | KDM4E | |
| SCHEMBL7572279 | 0.73 | FFAR4 (0.73) | LMNAFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701627-B2 | LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701627-B2 | LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-07-11 | — | — | US | disclosed |
| US-20150361038-A1 | LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE | 2015-12-17 | — | — | US | disclosed |
| US-20150361038-A1 | LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE | 2015-12-17 | — | — | US | disclosed |
| US-20150105438-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361038-A1 | LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS | LRRK2, PARK7, SNCA | LMNA 4379/4885MAPK1 501/4885KAT6A 1863/4885 |
| US-20150105438-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | QDPR, IDO1, ADRA1D | LMNA 3947/4885MAPK1 1916/4885KAT6A 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.